A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2016
At a glance
- Drugs MEDI 1814 (Primary) ; MEDI 1814 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.